ArticleGraefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie2026
Topical versus oral antiviral therapy for cytomegalovirus anterior uveitis: a multicenter study in Taiwan.
Article in Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo compare topical and oral antiviral therapies for cytomegalovirus (CMV) anterior uveitis (AU) in terms of efficacy.
methodsThis retrospective study included 240 patients with CMV AU who received treatment at Chang Gung Memorial Hospital between 2007 and 2019. Their diagnoses were confirmed through aqueous polymerase chain reaction.
resultsThe mean follow-up duration was 4.0 ± 3.1 years. The proportion of patients with an acute uveitis course, defined as no anti-CMV medication use beyond 3 months after diagnosis, was higher in patients initially treated with oral valganciclovir than in those initially treated with topical ganciclovir (40.0% vs. 15.7%; p = 0.038). Patients initially treated with topical ganciclovir plus oral valganciclovir were least likely to develop chronic disease (combined therapy vs. topical therapy vs. oral therapy: 5.0% vs. 39.3% vs. 20.0%; p = 0.007). Within 3 years, the risk of glaucoma surgery or laser intervention was lower in the acute group compared with the chronic (odds ratio [OR]: 0.25, 95% confidence interval [CI]: 0.08-0.82) and recurrent (OR: 0.32, 95% CI: 0.11-0.92) groups. The risk of corneal transplantation was lower in both the acute and chronic groups compared with the recurrent group (OR: 0.17, 95% CI: 0.05-0.56; and OR: 0.28, 95% CI: 0.09-0.86, respectively).
conclusionsCompared with topical ganciclovir, oral valganciclovir is associated with a lower risk of recurrent and chronic CMV AU. Chronic and recurrent disease are associated with increased risk of glaucoma requiring intervention, and recurrent disease carries an additional risk of corneal decompensation.
Indexed as
Identifiers
42726112What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.